European venture capital firm Truffle Capital has promoted Antoine Pau and Alexandre Ouimet-Storrs partner status.
Pau (35) joined Truffle Capital in 2008 as Investment Director in the life sciences sector. Formerly, he managed legal audits of pharmaceutical and biotech companies, as well as private equity fundsat Mazars, where Antoine also conducted financial due diligences for tech companies in the Transaction Services department.
Pau is a Board member of Theradiag (Alternext: ALTER), Abivax, Biokinesis, Deinobiotics and Diaccurate, all of them Truffle portfolio companies. A PharmD and an ESSEC graduate (MSc in Management), Pau is also an adjunct lecturer at Sciences Po Paris.
Ouimet-Storrs (34) joined Truffle Capital in 2011 as Investment Director in the energy and cleantech sector. Formerly, he worked at Air Liquide as an Energy Manager for Europe, working primarily on physical and financial cogeneration plant optimization. A co-founder of two startups in Canada, Ouimet-Storrs has a strong expertise in energy markets, cleantechs, remediation and power production technologies.
Ouimet-Storrs is a Board member of Dietswell (Alternext : ALDIE), Acerde, Actility, SP3H, Neelogy, OHT, Eco Carbone and 2B Energy, all of them Truffle portfolio companies. Ouimet-Storrs graduated from McGill University in Montreal with a Bachelors degree (2004) and a Masters (2006) in Chemical Engineering. From 2003 to 2004, Alexandre was elected as an administrator of McGill University.
“Antoine and Alexandre have great skills and a very sharp experience in their respective fields. They have demonstrated their ability to detect innovative high-growth potential companies. They have efficiently contributed to the structuring and optimisation of numerous investments in the life sciences, green chemistry and energy sectors. We are pleased to demonstrate our confidence in Alexandre and Antoine and to announce their promotion as Partners", say Henri Moulard, Dr Philippe Pouletty and Bernard-Louis Roques, co-founders of Truffle Capital.
